Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Scientific Officer | January 03, 2025 | January 07, 2025 |
| Lexeo Therapeutics, Inc.LXEO · Entity 5687 | Director | April 28, 2026 | April 30, 2026 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date January 03, 2025 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,388 |
Reported balance
After 2025-01-03 transaction · row 1
1 source rowRow 1 · 2025-01-03 · Sale · Disposed 8,966 · Balance 77,388 F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.
Lexeo Therapeutics, Inc.
Report date April 28, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 · Expires 2036-04-27 | Direct | 50,000 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service.
Taysha Gene Therapies, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,178 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 21,335 · Balance 127,178 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-01 | Direct | 42,671 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 42,671 · Balance 42,671 F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 42,671 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001777421-26-000005 · form4-06022026_040610.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,671 Underlying: Common Stock · 42,671 shares Expires 2036-06-01 F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 21,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001777421-26-000005 · form4-06022026_040610.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,178 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:01 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001777421-26-000003 · form4-04302026_080451.xml · derivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-04-27 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 113,246 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-25-015571 · form4-06042025_040601.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,246 Underlying: Common Stock · 113,246 shares Expires 2035-06-02 F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 56,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015571 · form4-06042025_040601.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,843 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:16 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,966 | $12.18 | $109,205.88 |
DisclosureSEC source: 0000950170-25-003002 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,388 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001232 · ownership.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-001232 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 98,440 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015038 · form4-05312024_040501.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,440 Underlying: Common Stock · 98,440 shares Expires 2034-05-29 F2 · derivative.exercise_date: The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 49,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015038 · form4-05312024_040501.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,220 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 54,794 | $0.00 Strike: $32.66 | $0.00 |
DisclosureSEC source: 0000950170-24-025907 · ownership.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,794 Underlying: Common Stock · 54,794 shares Expires 2034-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 37,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025907 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,893 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 667 | $29.38 | $19,596.46 |
DisclosureSEC source: 0000950170-24-003632 · ownership.xml · nonDerivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,927 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,608 | $28.66 | $46,085.28 |
DisclosureSEC source: 0000950170-24-003632 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,594 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:50 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,532 | $29.46 | $162,972.72 |
DisclosureSEC source: 0000950170-24-002514 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,202 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:35 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001210 · ownership.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:35 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-001210 · ownership.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:50 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 36,200 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-23-039733 · doc4.xml · derivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,200 Underlying: Common Stock · 36,200 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 42,302 | $0.00 Strike: $40.75 | $0.00 |
DisclosureSEC source: 0001209191-23-015742 · doc4.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,302 Underlying: Common Stock · 42,302 shares Expires 2033-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 29,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015742 · doc4.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,567 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 689 | $39.10 | $26,939.90 |
DisclosureSEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 3 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,629 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,641 | $38.22 | $62,719.02 |
DisclosureSEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,318 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:39 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,508 | $37.21 | $93,322.68 |
DisclosureSEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,959 F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001498 · doc4.xml · derivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 3,500 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F3 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001498 · doc4.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:41 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-038692 · doc4.xml · derivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,816 | $0.00 Strike: $79.85 | $0.00 |
DisclosureSEC source: 0001209191-22-015976 · doc4.xml · derivative · entry 5 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,816 Underlying: Common Stock · 13,816 shares Expires 2032-02-28 F6 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 13,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015976 · doc4.xml · nonDerivative · entry 3 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,631 F4 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| March 01, 2022 Filed Mar 5, 2022 01:58 UTC Amendment | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 20,203 | $0.00 Strike: $79.85 | $0.00 |
DisclosureSEC source: 0001209191-22-016526 · doc4a.xml · derivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,203 Underlying: Common Stock · 20,203 shares Expires 2032-02-28 F1 · shares: The original Form 4 incorrectly reported the number of options granted as 13,816. F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 13,816. F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 13,816. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 01:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015976 · doc4.xml · derivative · entry 4 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,500 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F5 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 01:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,148 | $112.25 | $128,863.00 |
DisclosureSEC source: 0001209191-22-015976 · doc4.xml · nonDerivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,815 F3 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 01:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015976 · doc4.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · derivative · entry 13 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 84,375 shares as of August 30, 2021. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · derivative · entry 12 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 27,000 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 30, 2021. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 207 | $160.47 | $33,217.29 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 11 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,391 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.40 to $160.53, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,653 | $159.64 | $423,524.92 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 10 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,598 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $160.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,515 | $158.90 | $240,733.50 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 9 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,251 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.31 to $159.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,932 | $157.77 | $620,351.64 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 8 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,766 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.305 to $158.245, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 7,425 | $156.79 | $1,164,165.75 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 7 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,698 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.22 to $157.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 16,115 | $155.61 | $2,507,655.15 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 6 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,123 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.22 to $156.19, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 28,669 | $154.77 | $4,437,101.13 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 5 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,238 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.22 to $155.215, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 20,645 | $153.64 | $3,171,897.80 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 4 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,907 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.16 to $154.15, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 15,839 | $152.75 | $2,419,407.25 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 3 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,552 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.16 to $153.155, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 70,000 | $14.25 | $997,500.00 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 2 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:34 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 27,000 | $13.40 | $361,800.00 |
DisclosureSEC source: 0001209191-21-054321 · doc4.xml · nonDerivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-050228 · doc4.xml · derivative · entry 9 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 26,000 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 126 | $141.63 | $17,845.38 |
DisclosureSEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 8 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,391 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · balance_after: Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,054 | $140.73 | $570,519.42 |
DisclosureSEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 7 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,772 | $139.85 | $387,664.20 |
DisclosureSEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 6 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,571 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,419 | $138.78 | $613,268.82 |
DisclosureSEC source: 0001209191-21-050228 · doc4.xml · nonDerivative · entry 5 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,343 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.